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Abstract DNA binds neutrophil elastase and mucus proteinase 
inhibitor as evidenced by affinity chromatography on elastase- 
Sepharose, inhibitor-Sepharose and DNA-cellulose. DNA is a 
potent hyperbolic inhibitor of elastase. The polynucleotide-en- 
~yme complex is partially active on synthetic substrates and 
on elastin. DNA strongly increases kd~ and Ki for the inhibition 
of elastase by mucus proteinase inhibitor 
kass 
t E + I ~ EI, K i = kdi~Jka~s). 
kdiss 
['he above effects are all salt-dependent. At physiological ionic 
strength, DNA is a potent inhibitor of the elastolytic activity of 
elastase and increases k~ and K~ for the elastase-mucus pro- 
teinase inhibitor interaction 160-fold and 100-fold, respectively. 
,~ey words': Elastase; Mucus proteinase inhibitor; Enzyme 
i:inetics; DNA;  Cystic fibrosis 
L. Introduction 
Neutrophil elastase (NE) is a 30-kDa cationic glycoprotein 
.vhose crystal structure is known. This serine proteinase cleaves 
t number of plasma and extracellular matrix proteins including 
,.:lastin. It is stored in the azurophil granules of neutrophils from 
,vhich it may be released following excessive phagocytosis or 
:ell death. Its extracellular proteolytic action is normally pre- 
,lented by protein proteinase inhibitors such as ~l-proteinase 
nhibitor, ~2-macroglobulin or mucus proteinase inhibitor 
MPI) (for a review see [1]). The latter is an 11.7-kDa unglyco- 
~ylated cationic protein composed of two domains of similar 
;ize and architecture ([2] and refs. therein). 
MPI is the most abundant NE inhibitor of airways secretions 
~here it occurs in concentrations as high as 5 / IM [3]. Despite 
~:his high load of inhibitor, bronchial secretions from patients 
~vith cystic fibrosis contain significant amounts of active NE [4]. 
On the other hand, these secretions also contain large quantities 
~f neutrophil-derived DNA [5]. This raises the question as to 
uhether DNA interferes with the inhibition of NE by MPI. The 
~resent investigation attempts to answer this question. 
2. Materials and methods 
2.1. Materials 
Human NE was purified from purulent sputum as described in [6]. 
Recombinant MPI was obtained from Synergen, Boulder, CO through 
the courtesy of Dr. H.P. Schnebli, Ciba-Geigy, Basel, Switzerland. NE 
and MPI were active site titrated as indicated in [6]. Stock solutions of 
Suc-Ala3-pNA and MeOSuc-Ala2-Pro-Val-pNA (Bachem, Bubendorf, 
Switzerland) were made in N-methylpyrolidone and dimethylforma- 
mide, respectively. The final concentration of organic solvent in the 
reaction mixtures was 2% (v/v) throughout. Remazol Brilliant-blue 
elastin (RBB-elastin) was purchased from Elastin Products Company 
(Owenville, MO). Salmon sperm DNA and DNA~cellulose came from 
Sigma. NE or MPI were coupled to epoxy-activated Sepharose (Phar- 
macia) as described by the manufacturer. The three affinity supports 
(4 ml) were poured into HR 10/10 Pharmacia columns and equilibrated 
with 50 mM HEPES buffer, pH 7.4. 
2.2. Determination of k,,, and K,~ 
The kinetic onstants kca t and Km for the hydrolysis of MeOSuc-Ala2- 
Pro-Val-pNA by 30 nM free or DNA-bound NE were determined by 
measuring the enzyme velocities as a function of the substrate concen- 
tration and fitting the data to the Michaelis-Menten equation using a 
nonlinear egression analysis program (ENZFITTER, Biosoft, Cam- 
bridge, UK). 
2.3. Elastolytic activity 
The effect of DNA on the elastolytic activity of NE was assessed as 
follows. Constants concentrations of NE were reacted with increasing 
concentrations of DNA in a total volume of 600/11. After 15 min at 
25°C, 500 ztl aliquots were withdrawn from these mixtures and added 
to 1,500/~1 of continuously stirred RBB-elastin suspensions. From time 
to time a 450/11 sample was withdrawn from these suspensions, diluted 
with 550/11 of 0.75 M acetate buffer pH 4.5, centrifuged at 10,000 × g 
and read at 595 nm to assay the concentration of soluble elastin pep- 
tides. A total of four aliquots were removed over a period of ca. 1 h. 
The rate of elastolysis was calculated from the slope of the linear 
relationship between -,4595 and time. The final concentration fNE and 
RBB-elastin were 2.5 ~tM and 3 mg/ml, respectively. 
2.4. Kinetics of inhibition of NE 
The rate of inhibition of NE by MPI was measured by reacting free 
or DNA-bound NE with a mixture of MPI and MeO-Suc-Ala2-Pro- 
Val-pNA and recording the release of p-nitroaniline at 410 nm. A 
SFA-12 rapid mixing accessory (Hi-Tech Scientific, Salisbury, UK) 
with a dead time of ca. 1 s was used to mix the reagents. Nonlinear 
regression analysis of the progress curves was done using the ENZFIT- 
TER software. The final concentrations ofNE, MPI and substrate were 
30 nM, 300 nM and 3 mM, respectively. 
All other technical details are given in the legends to the figures. 
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~lbbreviations: NE, neutrophil elastase; MPI, mucus proteinase inhibi- 
tor = secretory leucoprotease inhibitor (SLPI); Suc-Ala3-pNA, suc- 
cinyl-Ala3-p-nitroanilide; MeOSuc-Ala2-Pro-Val-pNA, methoxysuc- 
cinyl-Ala2-Pro-Val-p-nitroanilide; RBB-elastin, remazol Brilliant-blue 
elastin. 
3. Results 
3.1. DNA binds NE  and MP I  
Affinity chromatography was used to assess the interaction 
of DNA with NE and MPI. At low ionic strength (50 mM 
HEPES, pH 7.4) DNA binds to NE-Sepharose (Fig. 1A) and 
to MPI-Sepharose (Fig. 1B), A linear NaC1 gradient desorbs 
the polynucleotide from each column. On the other hand, NE 
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Fig. 1. Affinity chromatography of 50 #g of DNA on NE-Sepharose 
(panel A) and MPI-Sepharose (panel B) and of 300 #g of NE ( - - )  
and 210 #g of MPI ( . . . .  ) on DNA-cellulose (panel C). The columns 
were equilibrated with 50 mM HEPES, pH 7.4. DNA, NE, and MPI 
were dissolved in the same buffer and eluted from the columns with a 
linear NaC1 gradient at a flow-rate of 0.5 ml. min -~. 
and MPI bind to DNA-cellulose at low ionic strength and are 
eluted from the affinity column by a linear salt gradient (Fig. 
1C). NE has apparently a better affinity for DNA than MPI 
since its retention time on the DNA-cellulose column (42 s) is 
significantly longer than that of MP1 (33 s). The data of Fig. 
1C also suggest hat at a physiological ionic strength (0.15 M 
NaCI) the affinity of DNA for MPI is relatively weak whereas 
it is fairly strong for NE. 
3.2. Hyperbolic inhibition of NE by DNA 
Fig. 2 shows the effect of DNA on the rate of the NE- 
catalyzed hydrolysis of Suc-Ala3-pNA, a synthetic elastase sub- 
strate [7]. The enzyme velocity decreases sharply and then levels 
off, indicating that the NE-DNA complex is partially active, 
i.e. that the inhibition is hyperbolic. The enzyme-polynucleo- 
tide complex retains 20% and 70% activity of the free enzyme 
in the presence of 50 mM and 150 mM NaCI, respectively (see 
Fig. 2) and 30% activity in the presence of 100 mM NaC1 (data 
not shown). 
Hyperbolic inhibition [8] may be analyzed using Scheme 1 
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Km kcat 
E +S~-----ES - - - -~E+P 
+ + 
I I 
~K m flkca t 
E1 + S~ ESI ~ E1 + P 
Scheme 1. 
where E, S and I stand for enzyme, substrate and inhibitor, 
respectively and ~ and fl are dimensionless numbers. The con- 
ditions under which hyperbolic inhibition takes place may be 
summarized by 0 < fl -< 1; ~ > ~ - 1. We have determined 
and fl for the effect of DNA on the NE-catalyzed hydrolysis of 
MeO-Suc-Ala2-Pro-Val-pNA, a more specific NE substrate [9]. 
The results are reported in Table 1. It can be seen that DNA 
has two effects: (i) it increases Km (c~ > 1), i.e. it apparently acts 
as a 'competitive inhibitor' of NE, (ii) it forms an ESI complex 
that decomposes at a significant rate (0 < fl < 1), i.e. it is a 
hyperbolic inhibitor of NE. Ionic strength strongly decreases 
c~ but does not significantly change ft. As a consequence, the 
lower the ionic strength, the better the inhibition, a feature that 
also characterises the NE-catalyzed cleavage of Suc-Ala3-pNA 
(see Fig. 2). 
Fig. 3 shows the effect of DNA on the activity of NE on 
fibrous elastin, its natural substrate. The inhibition again ap- 
pears to be hyperbolic although the residual activities do not 
reach a true plateau. Higher DNA concentrations could not be 
used because the reaction media became cloudy and viscous. 
The inhibition curve obtained in the presence of 100 mM NaC1 
was found to lie between those obtained at 50 mM and 150 mM 
NaC1 (data not shown). The most striking feature observed 
with elastin is that at a physiological ionic strength, DNA is a 
potent inhibitor of the elastolytic activity of NE (Fig. 3) 
whereas it has a minor effect on the NE-catalyzed hydrolysis 
of the synthetic substrates (Fig. 2 and Table 1). 
3.3. DNA impairs the functional activity of MPI 
The kinetics of inhibition of NE by MPI was studied using 
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Fig. 2. Effect of DNA on the activity of NE on Suc-AIa3-pNA. Constant 
concentrations of NE were reacted with increasing concentrations of
DNA in a total volume of 980 #1 of 50 mM HEPES, pH 7.4 containing 
50 mM NaCl (©) or 150 mM NaC1 (e). After 15 rain at 25°C, 20#1 of 
50 mM Suc-Ala3-pNA were added and the absorbance was recorded at 
25°C. The final concentration of NE was 0.5 pM throughout. 
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] ig. 3. Effect of DNA on the elastolytic activity of NE. Constant 
c ~ncentrations of NE were reacted with increasing concentrations of 
I >NA. The residual enzymatic activities were then tested with RBB- 
elastin as described in the experimental section. The buffer was 50 mM 
t {EPES, pH 7.4, containing 50 mM NaCI (©) or 150 mM NaCI (o). The 
I nal concentration f NE was 2.5 pM throughout. 
t he progress curve method which consists of adding enzyme to 
mixture of inhibitor and substrate and recording the release 
~f product as a function of time [10]. Fig. 4 shows typical 
1,rogress curves run in the absence and presence of 200 flg/ml 
I )NA and at a physiological ionic strength. Both curves are 
t haracterised by a pre-steady-state followed by a steady-state 
t linear) release of product. DNA significantly shortens the du- 
T ation of the pre-steady-state phase and dramatically increases 
the steady-state velocity so that after a certain time, there is 
tnore product released in the presence of DNA than in its 
,~bsence. With lower DNA concentrations, milder effects were 
,,bserved (data not shown). 
The progress curves, analyzed as described previously [11], 
,ielded k, the pseudo-first-order rate constant describing the 
~re-steady-state, Vz and v~, the initial and steady-state v locities, 
espectively. These three parameters were used to calculate the 
iJnetic constants corresponding to the enzyme-inhibitor equi- 
kass 
i ibrium [12]: E + I ~ EI where E and I stand for free or DNA- 
kdiss 
~ound NE and MPI, respectively. For each DNA concentra- 
ion we calculated k .... kdi+s and K~ using the following relation- 
..hips [10]: 
"++ [I]0 v~)t " Kin) (1) 
+ais+ = k • v+ - - -  (2 )  
Vz 
Ifi = ka i Jk~ (3) 
Fig. 5 shows the influence of the concentration of DNA 
)n k .... kd~++ and Ki at physiological ionic strength. There is a 
fable 1 
Effect of DNA on the kinetic parameters ( ee Scheme 1) describing the 
~lE-catalysed hydrolysis of MeOSuc-Alaz-Pro-Val-pNA at pH 7.4 and 
~5°C 
~!aC1 (mM) 0~Km (pM) flk~,t (s ~) ~ ,8 
50 330 + 44 5.7 _+ 0.3 3,2 + 0.7 0.62 + 0.06 
L00 156 _+ 25 6.2 + 0.3 1,8 + 0.4 0.66 + 0.05 
!:50 176 _+ 21 6.8 +_ 0.3 1,3 + 0.3 0.72 + 0.05 
moderate increase in kas but a very strong increase in kdiss 
which varies from 1.1 x 10 -4 s -~ in the absence of DNA to 
1.8 x 10 -2 s -~ in the presence of 200/lg/ml DNA. This 164-fold 
increase is responsible in part for the ca. 100-fold increase in 
K~. At lower ionic strength the effect of DNA on the kinetic 
parameters was less pronounced (data not shown). For exam- 
ple, the largest increase in kay++ was 43-fold and 67-fold in the 
presence of 50 mM NaC1 and 100 mM NaCI, respectively. 
4.  D iscuss ion  
The binding of NE and MPI to DNA strongly decreases with 
the ionic strength. Therefore, it probably involves ionic interac- 
tions between some basic amino acid residues of the cationic 
proteins and some phospho-deoxyribosyl moieties of the ani- 
onic polymer. This binding impairs the functional activity of 
both NE and MPI: (i) DNA is a hyperbolic inhibitor of NE, 
i.e. the DNA-NE complex has a low but significant enzymatic 
activity, (ii) DNA strongly decreases the stability of the NE 
MPI complex by increasing koi~ and K~, i.e. the enzymatic activ- 
ity of the DNA NE complex is much more resistant to inhibi- 
tion by MPI than free NE. The effect of DNA on the NE/MPI 
system is reminiscent of that observed with heparin, another 
anionic polymer. Heparin is also a hyperbolic inhibitor of NE 
[13] which forms a tight complex with MPI [11]. However, 
unlike DNA, heparin strongly potentiates the inhibition of NE 
by MPI [11]. 
Our findings may have important pathophysiological bear- 
ing. Cystic fibrosis is a disease whose major clinical manifesta- 
tions are in the lung with accumulation of purulent mucus, 
bacterial infections, airway inflammation and obstruction and 
ultimately lung tissue destruction due to NE and other neutro- 
phil proteinases ([4] and refs. therein). Cystic fibrosis sputum 
contains high amounts of DNA (4 mg/ml on the average) [14]. 
This DNA originates from neutrophils, forms a complex with 
mucus glycoproteins, is entrapped in the water-insoluble frac- 
tion of sputum and is responsible in part for the high viscosity 
of airways secretions which leads to airways obstruction [5,15]. 
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Fig. 4. Progress curves for the inhibition of NE by MPI in the absence 
(A) or presence (B) of 200/lg/ml DNA. The concentrations of NE, MPI 
and substrate were as indicated in the experimental section. The buffer 
was: 50 mM HEPES, 150 mM NaCI, pH 7.4, 25°C. 
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Fig. 5. Kinetic constants describing the inhibition of NE by MPI in 
absence or presence of variable concentrations of DNA at 25°C and 
pH 7.4 (50 mM HEPES, 150 mM NaC1). The constants k,s~, kd~ss and 
Ki are given in (M -I 's-l× 10-6), (S-I× 10 -3) and (M x 109), respectively. 
The bars represent the standard errors calculated from repeated deter- 
minations. 
Recombinant DNase I has been shown in vitro to reduce the 
viscoelasticity of cystic fibrosis putum [16]. In addition, admin- 
istration of aerosolized enzyme improves the lung function of 
cystic fibrosis patients [17]. Our in vitro data strongly suggest 
that most of the NE released from neutrophils in cystic fibrosis 
airways ecretions i entrapped in insoluble DNA and therefore 
has little, if any, proteolytic activity. We therefore believe that 
long-term administration of DNase may have deleterious ef- 
fects on lung tissue proteins because it will release free and 
active NE from its complex with DNA. Since the concentration 
of MPI is much lower than that of NE in cystic fibrosis secre- 
tions [3,18], NE may attack lung tissue proteins in an unim- 
paired way. 
At physiological ionic strength the binding of MPI to DNA 
is relatively weak. In cystic fibrosis airways ecretions this poor 
affinity may, however, be largely compensated for by the 
enormous DNA concentration present in these fluids. Hence, 
it is likely that a large proportion of the MPI administered by 
aerosol to inhibit NE in lung secretions of cystic fibrosis pa- 
tients [4] will be entrapped in insoluble DNA and will, there- 
fore, not be available for NE inhibition. Also, the fraction of 
administered MPI which reacts with DNA-bound NE will form 
an unstable inhibitory complex as we have shown in vitro. The 
effects discussed here may explain why considerably high 
amounts of recombinant MPI are required to observe signifi- 
cant NE inhibition in lung secretion of cystic fibrosis patients 
[4]. 
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